ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the...

Related Keywords

Boston ,Massachusetts ,United States ,Montreal ,Quebec ,Canada ,Cambridge ,Cambridgeshire ,United Kingdom ,Toronto ,Ontario ,Canadian ,Johanne Kaplan ,Acumen Pharmaceuticals ,Alzheimer Disease Program ,Exchange Commission ,Promis Neurosciences Inc ,Company Phase ,Nasdaq ,Initiative For Translational Neuroscience ,Toronto Stock Exchange ,Announces Third Quarter ,Gail Farfel ,Chief Executive Officer ,Disease Program ,Investigation Review Board ,Chief Development Officer ,Translational Neuroscience ,Round Table ,Nasdaq Capital Market ,New Drug ,Drug Administration ,Collective Coordinates ,Disease Specific Epitopes ,Annual Report ,Post Effective Amendment ,Quarterly Reports ,Investor Relations ,Marie Fields ,Preferred Shares ,Consolidated Statements ,